Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New guidance on stem cell therapies
Stem cell medicines are produced in large batches which need to be sterile.
Document addresses concerns raised on sterility 

The first ever guidance for stem cell-based therapies in animals has been-been published by the European Medicines Agency (EMA).

The guidance follows a review of scientific evidence by the Committee for Medicinal Products for Veterinary Use (CVMP), which identified the sterility of stem-cell therapies as a ‘priority area’.

Taking the form of a question and answer document, the guidance addresses eight main concerns raised by manufacturers and authorities with regards to ensuring sterile and safe stem cell-based therapies.

Veterinary stem cell medicines originate from tissues from a donor from the same species of animal. They are produced in large batches which need to be sterile as they are administered by injection into the body.

Contamination can occur at various stages - from the initial sampling of cells and tissues, up to the final packaging into vials, syringes or bottles. The EMA states that the most critical step is the sourcing and collection of the stem cells as it is not always possible to put in place aseptic techniques at this stage.

Up to now, there has been no specific guidance from the EMA on how stem cell-based veterinary medicine should be used. Guidance documents have been produced for human cell-based products or for general requirements on animal cell-based products in the USA.

In recent years, interest and research into new therapies such as stem cell or gene therapy has gathered speed. In 2014, the EMA established an Ad Hoc expert group of veterinary novel therapies to provide general guidance on the requirements of novel veterinary medicines.

The EMA defines novel therapies as therapies that are entirely new to the veterinary sector. This is because they are genuinely new and have not been used in animals before, or new only to the veterinary sphere, but well known in human medicine.

 

 

 

Become a member or log in to add this story to your CPD history

Voting opens for BEVA Council

News Story 1
 Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.

There are five candidates standing for four available places on Council. They are:

  • Alexandre Triguino
  • Angela Jones
  • Beth Bryant
  • Holly Rees
  • Hugh Somerville
Full profiles for each candidate can be found on the BEVA website

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'